Phase I and pharmacokinetic study of MLN8054, a selective inhibitor of Aurora A kinase

被引：3
|
作者：
Dees, E. [1 ]
Infante, J. R. [2 ]
Cohen, R. B. [3 ]
O'Neil, B. [1 ]
Burris, H. [2 ]
von Mehren, M. [3 ]
Gray, G. [4 ]
Galvin, K. [5 ]
Manfredi, M. [5 ]
Eton, O. [6 ]
机构：
[1] UNC Lineberger Comprehens Canc Ctr, Chapel Hill, NC USA
[2] Sarah Cannon Res Inst, Nashville, TN USA
[3] Fox Chase Canc Ctr, Philadelphia, PA 19111 USA
[4] Millennium Pharmaceut Inc, Drug Dev, Cambridge, MA USA
[5] Millennium Pharmaceut Inc, Canc Pharmacol, Cambridge, MA USA
[6] Millennium Pharmaceut Inc, Oncol Clin Res, Cambridge, MA USA
来源：
EJC SUPPLEMENTS | 2008年 / 6卷 / 12期
关键词：
D O I：
10.1016/S1359-6349(08)72215-8
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：91 / 91
页数：1
相关论文
共 50 条
  • [31] Phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of MLN8237, a novel selective aurora A kinase (AAK) inhibitor, in patients (pts) with advanced solid tumors
    Cervantes-Ruiperez, A.
    Elez, M. E.
    Rosello, S.
    Macarulla, T.
    Rodriguez-Braun, E.
    Lee, Y.
    Ecsedy, J.
    Liu, H.
    Fingert, H.
    Tabernero, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [32] Broad-based anti-tumor activity of the Aurora A kinase inhibitor, MLN8054.
    Zhang, MK
    Burenkova, O
    Chandra, S
    Connolly, K
    Huck, J
    Manfredi, MG
    Saylor, M
    Zhang, YM
    Meetze, KA
    CLINICAL CANCER RESEARCH, 2005, 11 (24) : 9082S - 9082S
  • [33] Crystal structure of an Aurora-A mutant that mimics Aurora-B bound to MLN8054: insights into selectivity and drug design
    Dodson, Charlotte A.
    Kosmopoulou, Magda
    Richards, Mark W.
    Atrash, Butrus
    Bavetsias, Vassilios
    Blagg, Julian
    Bayliss, Richard
    BIOCHEMICAL JOURNAL, 2010, 427 : 19 - 28
  • [34] Molecular dynamics and free energy studies on Aurora kinase A and its mutant bound with MLN8054: insight into molecular mechanism of subtype selectivity
    Yang, Ying
    Shen, Yulin
    Li, Shuyan
    Jin, Nengzhi
    Liu, Huanxiang
    Yao, Xiaojun
    MOLECULAR BIOSYSTEMS, 2012, 8 (11) : 3049 - 3060
  • [35] Pediatric Phase I Trial and Pharmacokinetic Study of MLN8237, an Investigational Oral Selective Small-Molecule Inhibitor of Aurora Kinase A: A Children's Oncology Group Phase I Consortium Study
    Mosse, Yael P.
    Lipsitz, Emily
    Fox, Elizabeth
    Teachey, David T.
    Maris, John M.
    Weigel, Brenda
    Adamson, Peter C.
    Ingle, Mark A.
    Ahern, Charlotte H.
    Blaney, Susan M.
    CLINICAL CANCER RESEARCH, 2012, 18 (21) : 6058 - 6064
  • [36] Phase I Study of Aurora A Kinase Inhibitor Alisertib (MLN8237) in Combination With Selective VEGFR Inhibitor Pazopanib for Therapy of Advanced Solid Tumors
    Shah, Hiral A.
    Fischer, James H.
    Venepalli, Neeta K.
    Danciu, Oana C.
    Christian, Sonia
    Russell, Meredith J.
    Liu, Li C.
    Zacny, James P.
    Dudek, Arkadiusz Z.
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2019, 42 (05): : 413 - 420
  • [37] Phase I Study of An Investigational Aurora A Kinase Inhibitor MLN8237 In Patients with Advanced Hematologic Malignancies
    Padmanabhan, Swaminathan
    Shea, Thomas C.
    Vose, Julie M.
    Reeder, Craig B.
    Berdeja, Jesus G.
    McDonagh, Kevin T.
    Goy, Andre
    Kelly, Kevin R.
    Zhou, Xiaofei
    Liu, Hua
    Fingert, Howard
    Fowler, Nathan
    BLOOD, 2010, 116 (21) : 1154 - 1154
  • [38] Phase I and pharmacological study of AZD1152, a selective inhibitor of aurora kinase B
    Boss, D. S.
    Witteveen, P. O.
    Mergui, M.
    van der Sar, J.
    Stockman, P. K.
    Voest, E. E.
    Beijnen, J. H.
    Schellens, J. H. M.
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2009, 68 (05) : 782 - 783
  • [39] Phase I study of the investigational drug MLN8237, an Aurora a kinase (AAK) inhibitor, in patients (pts) with solid tumors
    Dees, E. C.
    Infante, J. R.
    Burris, H. A.
    Astsaturov, I. A.
    Stinchcombe, T.
    Liu, H.
    Galvin, K.
    Venkatakrishnan, K.
    Fingert, H. J.
    Cohen, R. B.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [40] Phase I Pharmacokinetic and Pharmacodynamic Study of the Aurora Kinase Inhibitor Danusertib in Patients With Advanced or Metastatic Solid Tumors
    Steeghs, Neeltje
    Eskens, Ferry A. L. M.
    Gelderblom, Hans
    Verweij, Jaap
    Nortier, Johan W. R.
    Ouwerkerk, Jan
    van Noort, Conny
    Mariani, Mariangela
    Spinelli, Riccardo
    Carpinelli, Patrizia
    Laffranchi, Bernard
    de Jonge, Maja J. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (30) : 5094 - 5101
12345